TCT) shows the least negative ROIC to WACC ratio, suggesting relative efficiency in using capital.Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is a biopharmaceutical company that focuses on developing treatments for rare and ultra-rare genetic diseases. The company is part of a competitive landscape that includes peers like PTC Therapeutics, Blueprint Medicines, Agios Pharmaceuticals, and uniQure. These companies are also engaged in the development of innovative therapies for rare conditions.
Ultragenyx has a Return on Invested Capital (ROIC) of -45.95% and a Weighted Average Cost of Capital (WACC) of 8.86%. This results in a ROIC to WACC ratio of -5.18, indicating that the company is not generating sufficient returns to cover its cost of capital. This negative ratio suggests inefficiencies in capital utilization.
In comparison, PTC Therapeutics (NASDAQTCT) has a ROIC of -21.21% and a WACC of 10.24%, leading to a ROIC to WACC ratio of -2.07. Although still negative, PTC Therapeutics has the least negative ratio among its peers, suggesting it is relatively more efficient in using its capital.
Blueprint Medicines (NASDAQ:BPMC) and Agios Pharmaceuticals (NASDAQ:AGIO) also show negative ROIC to WACC ratios of -2.29 and -3.08, respectively. Despite their negative ratios, they are more efficient than Ultragenyx in terms of capital utilization, as highlighted by their less negative figures.
uniQure (NASDAQ:QURE) has a ROIC of -36.68% and a WACC of 5.53%, resulting in a ROIC to WACC ratio of -6.63. This is the most negative ratio among the peers, indicating significant challenges in generating returns that cover the cost of capital.
